Francisco Velazquez, MD
Internal Medicine · Bellaire, TXNPI 1922096197
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,957 of the $4,589 with a category attached, or 86.2%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,774 and has fallen 58.4% since, to $739 in 2025.
Across 153 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Research Institute, Inc.$980
- Gilead$484
- Amgen$448
- AstraZeneca$351
- Viiv Healthcare Company$276
- Teva Pharmaceuticals USA, Inc.$211
- plus $2K from 26 others
Across 1,205 payments — averaging $9652.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$8.1M
- Regeneron$1M
- Novartis$770K
- AbbVie$695K
- Astellas Pharma Global Development$646K
- Ironwood Pharmaceuticals, Inc$90K
- plus $271K from 13 others
What the payments were for
- Travel & lodging$62614%
- Food & beverage$3,95786%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Research Institute, Inc. | 2 | $980 |
| Gilead | 28 | $484 |
| Amgen | 15 | $448 |
| AstraZeneca | 8 | $351 |
| Viiv Healthcare Company | 14 | $276 |
| Teva Pharmaceuticals USA, Inc. | 5 | $211 |
| Antares Pharma, Inc. | 11 | $210 |
| Lilly USA, LLC | 7 | $187 |
| AbbVie(2 entities) | 9 | $175 |
| Novo Nordisk | 2 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $130 |
| Pfizer | 5 | $120 |
| Azurity Pharmaceuticals, Inc. | 6 | $108 |
| Stryker | 1 | $97 |
| Esperion Therapeutics, Inc. | 5 | $94 |
| Johnson & Johnson | 4 | $89 |
| Eisai Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Tolmar, Inc. | 3 | $51 |
| GSK | 2 | $47 |
| Astellas Pharma Global Development | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Abbott | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $23 |
| Napo Pharmaceuticals Inc | 1 | $22 |
| Merck | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$255
- Repatha$222
- Yeztugo$122
- Wegovy$116
- Austedo XR$113
How this compares
$4,589 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $58,681 |
| CreonLipase/Protease/Amylase | 14 | $34,243 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,899 |
| FarxigaDapagliflozin Propanediol | 17 | $18,641 |
| MyrbetriqMirabegron | 19 | $12,134 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $1,429 |
| Tamsulosin Hcl | 40 | $1,207 |
| SynthroidLevothyroxine Sodium | 12 | $728 |
| Rosuvastatin Calcium | 70 | $703 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $672 |
| Atorvastatin Calcium | 67 | $659 |
| Quetiapine Fumarate | 23 | $628 |
| Metoprolol Succinate | 39 | $615 |
| Bupropion XlBupropion Hcl | 13 | $600 |
| Olmesartan Medoxomil | 25 | $536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Descovy | $484 | $84,58025 claims |
| AbbVieCreon, Synthroid | $175 | $34,97126 claims |
| AstraZenecaFarxiga | $351 | $18,64117 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $12,13419 claims |
| PfizerPaxlovid | $120 | $1,42915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Bellaire
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.